Project Grant K01CA297060
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$192K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The federal Project Grant award F31CA295091 is funded by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program. The $119,922 award supports research to investigate the role of the Fanconi Anemia (FA) pathway in driving a chromosomal abnormality called chromothripsis, which is frequently observed in cancer genomes. The research aims to comprehensively identify regions of micronucleated chromosomes undergoing FA pathway processing during mitosis, and to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $342,102 to The Johns Hopkins University to conduct research on the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). The research aims to elucidate the mechanisms by which HMGA1 drives leukemogenesis and therapy resistance in this aggressive form of AML, which is resistant to current treatments. The project will involve defining the role of...
This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
The National Cancer Institute (NCI) awarded a $257,872 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The University of Texas MD Anderson Cancer Center. The grant supports a 2-year research project titled "Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling". The project aims to elucidate the cellular and genetic mechanisms underlying the initiation of esophageal squamous cell carcinoma (ESCC), a lethal cancer with a 10-25% 5-year...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $162,756 to The Regents of the University of California, San Francisco (UCSF) from April 1, 2025 to March 31, 2027. The award aims to validate a transcriptomic biomarker that correlates with aneuploidy and chromosomal instability in meningiomas, a common type of brain tumor. The funded research will also utilize mouse and in-vitro models to define the role...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $690,772 to New York University School of Medicine to conduct research on mapping and targeting 3D regulatory elements in leukemia and lymphoma. The key objectives are to: A) Extensively map 3D chromatin "hubs" - DNA elements that interact with multiple loci - in primary peripheral T-cell lymphoma (PTCL) specimens. B) Perform CRISPR screens to identify biologically...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Trustees of Columbia University in the City of New York provides $2,775,137 to conduct research on the role of aging-related factors in the transformation of pre-leukemic conditions to acute myeloid leukemia (AML). The key objectives are to 1) establish how transcriptional deregulation, inflammatory signals, and stromal niche interactions promote clonal outgrowth of pre-leukemic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $125,783.00 to The University of Texas MD Anderson Cancer Center to conduct research on advanced gastric adenocarcinoma (GAC). The key objectives are to: 1) Determine the mechanisms of CDH1-inactivated advanced GAC progression, focusing on the roles of SOX4 and EZH2; and 2) Evaluate molecular subtype-based responses to immune checkpoint blockade. The research leverages murine organoid...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy. The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and...